Erasca Inc (NAS:ERAS)
$ 18.31 +0.20 (+1.13%) Market Cap: 6.36 Bil Enterprise Value: 6.16 Bil PE Ratio: 0 PB Ratio: 14.42 GF Score: 22/100

Erasca Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2026 / 09:30PM GMT
Release Date Price: $7.51 (+20.47%)
Anupam Rama
JPMorgan Chase & Co - Analyst

All right, let's go ahead and get started. Welcome everyone to the forty-fourth annual JPMorgan Healthcare Conference. My name is Anu Pamrama. I am one of the Smidcap biotech analysts here at JPMorgan. I'm joined by my squad, Rati Pinhey, Priyanka Gorover, and, Joyce Zhao.

Our next presenting company is Araska, and presenting on behalf of the company, we have CEO Jonathan Lim.

Jonathan Lim
Erasca Inc - Chairman of the Board, Chief Executive Officer, Co-Founder

Thank you, Anna.

Good afternoon, everyone. It's great to see all of you here. 2026 is off to a very exciting start, and I look forward to telling you more about what's in store for Alaska. Before I do so, I will be making forward-looking statements, so I encourage you to visit our website at Araska.com to find our latest SEC filings.

At AASCA, our aim is to, basically aligned around our mission to erase cancer and also to eradicate RAS-driven cancer. So it's a portmanteau with a double meaning. I started this company with Kavon

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot